N
Naoto T. Ueno
Researcher at University of Texas MD Anderson Cancer Center
Publications - 390
Citations - 13778
Naoto T. Ueno is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Inflammatory breast cancer. The author has an hindex of 59, co-authored 389 publications receiving 11623 citations. Previous affiliations of Naoto T. Ueno include University of Texas Health Science Center at Houston & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
Marcos de Lima,Athanasios Anagnostopoulos,Mark F. Munsell,Munir Shahjahan,Naoto T. Ueno,Cindy Ippoliti,Borje S. Andersson,James Gajewski,Daniel R. Couriel,Jorge E. Cortes,Michele L. Donato,Joyce Neumann,Richard E. Champlin,Sergio Giralt +13 more
TL;DR: In a multivariate analysis of patient- and treatment-related prognostic factors, progression-free survival was improved after FM, for patients in CR at transplantation, and for those with intermediate-risk cytogenetics.
Journal ArticleDOI
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
Issa F. Khouri,Peter McLaughlin,Rima M. Saliba,Chitra Hosing,Martin Korbling,Ming S. Lee,L. Jeffrey Medeiros,Luis Fayad,Felipe Samaniego,Amin M. Alousi,Paolo Anderlini,Daniel R. Couriel,Marcos de Lima,Sergio Giralt,Sattva S. Neelapu,Naoto T. Ueno,Barry I. Samuels,Fredrick B. Hagemeister,Larry W. Kwak,Richard E. Champlin +19 more
TL;DR: The described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma and all 18 patients who were tested and had evidence of JH/bcl-2 fusion transcripts in the bone marrow at study entry experienced continuous molecular remission.
Journal ArticleDOI
A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer
Ankur K. Nagaraja,Chad J. Creighton,Zhifeng Yu,Huifeng Zhu,Preethi H. Gunaratne,Preethi H. Gunaratne,Jeffrey G. Reid,Jeffrey G. Reid,Emuejevoke Olokpa,Hiroaki Itamochi,Naoto T. Ueno,Shannon M. Hawkins,Matthew L. Anderson,Martin M. Matzuk +13 more
TL;DR: Strong candidate miRNAs and their target genes that may contribute to the pathogenesis of clear cell ovarian cancer are revealed, thereby highlighting alternative therapeutic strategies for the treatment of this deadly cancer.
Journal ArticleDOI
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
Young Seok Ju,Young Seok Ju,Inigo Martincorena,Moritz Gerstung,Moritz Gerstung,Mia Petljak,Ludmil B. Alexandrov,Ludmil B. Alexandrov,Raheleh Rahbari,David C. Wedge,Helen Davies,Manasa Ramakrishna,Anthony Fullam,Sancha Martin,Christopher Alder,Nikita Patel,Steve Gamble,Sarah O’Meara,Dilip Giri,Torril Sauer,S. Pinder,Colin A. Purdie,Åke Borg,Henk Stunnenberg,Marc J. van de Vijver,Benita Kiat Tee Bk Tan,Carlos Caldas,Andrew Tutt,Andrew Tutt,Naoto T. Ueno,Laura Van't Veer,John W.M. Martens,Christos Sotiriou,Stian Knappskog,Paul N. Span,Sunil R. Lakhani,Jorunn E. Eyfjord,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Andrea L. Richardson,Alastair M Thompson,Alain Viari,Matthew Me Hurles,Serena Nik-Zainal,Peter J. Campbell,Michael R. Stratton +45 more
TL;DR: Insight is provided into the mutation rates, mutational processes and developmental outcomes of cell dynamics that operate during early human embryogenesis and it is demonstrated that the two daughter cells of many early embryonic cell-doubling events contribute asymmetrically to adult blood at an approximately 2:1 ratio.
Journal ArticleDOI
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center
Naoto T. Ueno,Aman U. Buzdar,Sonja E. Singletary,Fred C. Ames,Marsha D. McNeese,Frankie A. Holmes,Richard L. Theriault,Eric A. Strom,Barbara J. Wasaff,Lina Asmar,Debbie Frye,Gabriel N. Hortobagyi +11 more
TL;DR: In this paper, the authors reviewed the 20 years of experience at M. D. Anderson Cancer Center with a combined-modality approach against inflammatory breast carcinoma and found that a significant fraction of patients (28%) remained free of disease beyond 15 years.